{"id":58567,"date":"2026-03-02T14:20:06","date_gmt":"2026-03-02T06:20:06","guid":{"rendered":"https:\/\/flcube.com\/?p=58567"},"modified":"2026-03-02T14:20:07","modified_gmt":"2026-03-02T06:20:07","slug":"lynk-pharmas-zemprocitinib-hits-phase-iii-endpoints-in-atopic-dermatitis-best-in-class-jak1-inhibitor-shows-superior-efficacy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58567","title":{"rendered":"Lynk Pharma&#8217;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy"},"content":{"rendered":"\n<p><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> announced <strong>positive topline results<\/strong> from a <strong>Phase III study<\/strong> for <strong>zemprocitinib<\/strong> in <strong>moderate\u2011to\u2011severe atopic dermatitis (AD)<\/strong>. Both dose groups (<strong>12\u202fmg and 24\u202fmg<\/strong>) demonstrated <strong>highly statistically significant efficacy<\/strong> vs. placebo across <strong>primary and key secondary endpoints (p\u202f&lt;\u202f0.0001)<\/strong>, with <strong>good safety and tolerability profiles<\/strong>. The data support <strong>best\u2011in\u2011class potential<\/strong> for the <strong>second\u2011generation JAK1 inhibitor<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-results-summary\">Phase III Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Zemprocitinib 12\u202fmg<\/th><th>Zemprocitinib 24\u202fmg<\/th><th>Placebo<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Significant improvement<\/td><td>Significant improvement<\/td><td>Baseline<\/td><td><strong>p\u202f&lt;\u202f0.0001<\/strong><\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Significant improvement<\/td><td>Significant improvement<\/td><td>Baseline<\/td><td><strong>p\u202f&lt;\u202f0.0001<\/strong><\/td><\/tr><tr><td><strong>Safety\/Tolerability<\/strong><\/td><td>Good<\/td><td>Good<\/td><td>\u2014<\/td><td>Consistent profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-zemprocitinib\">Drug Profile \u2013 Zemprocitinib<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Class<\/strong><\/td><td>Second\u2011generation <strong>JAK1 inhibitor<\/strong><\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td><strong>Highly selective<\/strong> for JAK1 vs. JAK2\/3\/TYK2<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Best\u2011in\u2011class potential<\/strong> vs. first\u2011gen JAK inhibitors<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Potent, dose\u2011dependent inhibition of JAK1\u2011mediated inflammatory signaling pathways<\/td><\/tr><tr><td><strong>Safety Advantage<\/strong><\/td><td>Reduced off\u2011target effects \u2192 lower risk of adverse reactions (vs. pan\u2011JAK or JAK1\/2 inhibitors)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-indications\">Pipeline Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Atopic Dermatitis (AD)<\/strong><\/td><td><strong>Phase III positive topline<\/strong><\/td><\/tr><tr><td><strong>Rheumatoid Arthritis<\/strong><\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Ankylosing Spondylitis<\/strong><\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Vitiligo<\/strong><\/td><td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Best\u2011in\u2011Class Validation:<\/strong> The <strong>p\u202f&lt;\u202f0.0001 efficacy<\/strong> and <strong>favorable safety profile<\/strong> position zemprocitinib as a <strong>potential best\u2011in\u2011class JAK1 inhibitor<\/strong>, differentiating from <strong>upadacitinib (AbbVie)<\/strong> and <strong>abrocitinib (Pfizer)<\/strong> through <strong>superior selectivity<\/strong>.<\/li>\n\n\n\n<li><strong>AD Market Leadership:<\/strong> Atopic dermatitis represents a <strong>$15\u202fbillion+ global market<\/strong>; Phase III success enables <strong>NDA submission<\/strong> and potential <strong>first\u2011in\u2011class JAK1 positioning<\/strong> in China and global markets.<\/li>\n\n\n\n<li><strong>Selectivity Advantage:<\/strong> <strong>JAK1\u2011specific inhibition<\/strong> (vs. JAK1\/2 or pan\u2011JAK) may confer <strong>superior cardiovascular and thrombotic safety profiles<\/strong>, addressing <strong>black box warnings<\/strong> limiting first\u2011generation JAK inhibitor adoption.<\/li>\n\n\n\n<li><strong>Pipeline Breadth:<\/strong> Positive AD data de\u2011risks <strong>rheumatoid arthritis, ankylosing spondylitis, and vitiligo<\/strong> programs, supporting <strong>multi\u2011indication blockbuster potential<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>JAK Inhibitor Market<\/strong><\/td><td>~\u202f$15\u202fbillion across immunology; safety concerns with first\u2011gen (Xeljanz, Olumiant) create demand for selective alternatives<\/td><\/tr><tr><td><strong>AD Competitive Landscape<\/strong><\/td><td>Dupixent (IL\u20114R\u03b1) dominates biologics; JAK1 inhibitors (Rinvoq, Cibinqo) growing share; zemprocitinib&#8217;s selectivity may capture safety\u2011conscious prescribers<\/td><\/tr><tr><td><strong>China Market Dynamics<\/strong><\/td><td>Domestic JAK1 innovation prioritized; Lynk Pharma positioned for <strong>China\u2011first approval<\/strong> with global out\u2011licensing potential<\/td><\/tr><tr><td><strong>Vitiligo Expansion<\/strong><\/td><td>Emerging high\u2011value indication with no approved targeted therapies; JAK1 inhibition shows promise in repigmentation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NDA submission timelines, regulatory approvals, and commercial potential for zemprocitinib. Actual results may differ due to risks including competitive JAK1 inhibitor launches, long\u2011term safety monitoring requirements, and pricing pressure in the AD market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,1351],"class_list":["post-58567","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk Pharma&#039;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib in moderate\u2011to\u2011severe atopic dermatitis (AD). Both dose groups (12\u202fmg and 24\u202fmg) demonstrated highly statistically significant efficacy vs. placebo across primary and key secondary endpoints (p\u202f&lt;\u202f0.0001), with good safety and tolerability profiles. The data support best\u2011in\u2011class potential for the second\u2011generation JAK1 inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58567\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharma&#039;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib in moderate\u2011to\u2011severe atopic dermatitis (AD). Both dose groups (12\u202fmg and 24\u202fmg) demonstrated highly statistically significant efficacy vs. placebo across primary and key secondary endpoints (p\u202f&lt;\u202f0.0001), with good safety and tolerability profiles. The data support best\u2011in\u2011class potential for the second\u2011generation JAK1 inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58567\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T06:20:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T06:20:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58567#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58567\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharma&#8217;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy\",\"datePublished\":\"2026-03-02T06:20:06+00:00\",\"dateModified\":\"2026-03-02T06:20:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58567\"},\"wordCount\":431,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58567#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58567\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58567\",\"name\":\"Lynk Pharma's Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-02T06:20:06+00:00\",\"dateModified\":\"2026-03-02T06:20:07+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib in moderate\u2011to\u2011severe atopic dermatitis (AD). Both dose groups (12\u202fmg and 24\u202fmg) demonstrated highly statistically significant efficacy vs. placebo across primary and key secondary endpoints (p\u202f&lt;\u202f0.0001), with good safety and tolerability profiles. The data support best\u2011in\u2011class potential for the second\u2011generation JAK1 inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58567#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58567\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58567#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharma&#8217;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharma's Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib in moderate\u2011to\u2011severe atopic dermatitis (AD). Both dose groups (12\u202fmg and 24\u202fmg) demonstrated highly statistically significant efficacy vs. placebo across primary and key secondary endpoints (p\u202f&lt;\u202f0.0001), with good safety and tolerability profiles. The data support best\u2011in\u2011class potential for the second\u2011generation JAK1 inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58567","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharma's Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy","og_description":"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib in moderate\u2011to\u2011severe atopic dermatitis (AD). Both dose groups (12\u202fmg and 24\u202fmg) demonstrated highly statistically significant efficacy vs. placebo across primary and key secondary endpoints (p\u202f&lt;\u202f0.0001), with good safety and tolerability profiles. The data support best\u2011in\u2011class potential for the second\u2011generation JAK1 inhibitor.","og_url":"https:\/\/flcube.com\/?p=58567","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T06:20:06+00:00","article_modified_time":"2026-03-02T06:20:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58567#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58567"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharma&#8217;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy","datePublished":"2026-03-02T06:20:06+00:00","dateModified":"2026-03-02T06:20:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58567"},"wordCount":431,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Lynk Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58567#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58567","url":"https:\/\/flcube.com\/?p=58567","name":"Lynk Pharma's Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-02T06:20:06+00:00","dateModified":"2026-03-02T06:20:07+00:00","description":"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a Phase III study for zemprocitinib in moderate\u2011to\u2011severe atopic dermatitis (AD). Both dose groups (12\u202fmg and 24\u202fmg) demonstrated highly statistically significant efficacy vs. placebo across primary and key secondary endpoints (p\u202f&lt;\u202f0.0001), with good safety and tolerability profiles. The data support best\u2011in\u2011class potential for the second\u2011generation JAK1 inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58567#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58567"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58567#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharma&#8217;s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows Superior Efficacy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58567"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58567\/revisions"}],"predecessor-version":[{"id":58569,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58567\/revisions\/58569"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}